2022
When insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugsChapter 12 Medications for the Treatment of Type II Diabetes
Van Name M. Chapter 12 Medications for the Treatment of Type II Diabetes. 2019, 101-106. DOI: 10.1016/b978-0-323-55138-0.00012-7.Chapters
2018
The present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2016
Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL. Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study. Diabetes Technology & Therapeutics 2016, 18: 794-799. PMID: 27996320, PMCID: PMC5178000, DOI: 10.1089/dia.2016.0311.Peer-Reviewed Original ResearchConceptsClosed-loop insulin deliveryPlasma glucoseEnd of exercisePG levelsExercise studiesInsulin deliveryExercise periodCL insulin deliveryExercise-induced loweringType 1 diabetes subjectsExercise-induced reductionRecovery periodBrisk treadmillDL increaseRescue treatmentDiabetes subjectsInsulin infusionExerciseInsulinSimilar differencesVisitsCL controlDeliveryGlucosePeriod
2015
Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance
Van Name M, Giannini C, Santoro N, Jastreboff AM, Kubat J, Li F, Kursawe R, Savoye M, Duran E, Dziura J, Sinha R, Sherwin RS, Cline G, Caprio S. Blunted suppression of acyl‐ghrelin in response to fructose ingestion in obese adolescents: The role of insulin resistance. Obesity 2015, 23: 653-661. PMID: 25645909, PMCID: PMC4548801, DOI: 10.1002/oby.21019.Peer-Reviewed Original ResearchConceptsAcyl ghrelinObese insulinGlucose ingestionInsulin resistanceObese adolescentsCross-over designFructose ingestionGut hormonesChildhood obesityInsulin sensitivityFructose consumptionEffect of glucoseDiminished suppressionRandom orderIngestionObesityPYYAdolescentsInsulinSuppression differencesGlucoseMinutesResponseGhrelinOIR